指南与共识乳腺癌

原发保乳治疗后第二同侧乳腺癌事件的局部管理:国际德尔菲共识

Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus.
指南 / 共识 · Lancet Oncol · 2026-07-29

该国际德尔菲共识由美欧外科与放疗学会支持,针对原发保乳治疗后第二同侧乳腺癌事件(iBCE)的局部治疗,经两轮36名专家小组问卷达成共识。97个条目中78个(80%)达成共识,认为患者偏好是决策核心,再次保乳对选定患者是合理选择,并明确适宜再次保乳的间隔、分子分型等标准。

要点

  • 患者偏好是第二iBCE局部治疗决策的核心。
  • 再次保乳对选定患者是合理选项,需评估间隔≥60个月等标准。
  • HER2阳性或三阴性并非再次保乳的绝对禁忌。

核心结论

  • 国际德尔菲共识为第二同侧乳腺癌事件的局部管理提供结构化指导,支持共享决策与个体化治疗规划。

研究设计与样本

  • 由美欧外科与放疗学会支持,核心组8名专家制定问卷,采用德尔菲法对36名专家小组进行两轮调查,共识阈值预设为75%及以上同意。

主要发现

  • 两轮后97个条目中78个(80%)达成共识,100%专家同意患者偏好是决策核心且再次保乳对选定患者是合理选项。
  • 与再次保乳更适宜相关的标准包括两次手术间隔至少60个月、低风险加速部分乳腺照射分类、luminal分子分型及首次保乳无3级晚期毒性。
  • HER2阳性或三阴性亚型不被视为绝对禁忌,肿瘤与乳房体积比、清晰手术切缘及瘤床再照射也获强共识。
  • 全乳切除患者中,即刻自体组织重建获94%偏好,高于假体重建的75%。

关键数值与推荐

  • 共识定义为专家同意率75%或更高。
  • 再次保乳适宜标准包括手术间隔至少60个月、低风险加速部分乳腺照射分类、luminal分子分型及首次保乳无3级晚期毒性。
  • 全乳切除后即刻自体组织重建获94%偏好,假体重建获75%偏好。

临床怎么用

  • 临床决策应纳入患者偏好,对符合间隔≥60个月、luminal分型等标准的选定患者可考虑再次保乳。
  • HER2阳性或三阴性不应作为再次保乳的绝对排除标准。
  • 需重视肿瘤与乳房体积比、清晰手术切缘及瘤床再照射。
  • 全乳切除时优先考虑即刻自体组织重建。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Management of second ipsilateral breast cancer events (iBCEs) remains controversial, and there is a need to collate existing evidence and international guidance on patient selection and local treatment strategies. This project, endorsed by US and European surgical and radiation oncology societies, aimed to gather expert consensus on these issues. A questionnaire on second iBCE local treatment was developed and reviewed by a core group of eight experts, and Delphi methodology was applied over two rounds to 36 panellists, including radiation oncologists, breast surgeons, a plastic surgeon, and medical physicists. Consensus was predefined as agreement of 75% or higher. After two rounds, consensus was reached for 78 (80%) of 97 items. Panellists agreed that patient preferences are central to decision making (100%) and that a second breast-conserving therapy represents a reasonable option for selected patients (100%). Criteria associated with greater suitability for second breast-conserving therapy included an interval between surgeries of at least 60 months, low-risk accelerated partial breast irradiation classification, luminal molecular profile, and no grade 3 late toxicity related to the first breast-conserving therapy. HER2 (also known as ERBB2)-positive or triple negative subtypes were not viewed as absolute contraindications. Strong consensus was also observed regarding the importance of tumour-to-breast volume ratio, clear surgical margins, and tumour bed reirradiation. For patients undergoing mastectomy, immediate autologous reconstruction was preferred (94%) over implant-based approaches (75%). This international Delphi consensus offers structured guidance for the local management of second iBCE and supports shared decision making and individualised treatment planning.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Hannoun-Levi JM, Margenthaler JA, Anderson B, et al. Local management of second ipsilateral breast cancer events after primary breast-conserving therapy: an international Delphi consensus. Lancet Oncol. 2026. PMID: 42526471. doi:10.1016/S1470-2045(26)00177-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。